Company ProfilePremium

Dawnrays Pharmaceutical (Holdings) Limited

Company Profile Analysis

Ticker: 2348.HK東瑞製葯

ESOMAR 23 Corporate BadgeISO Certifications Badge
Dawnrays Pharmaceutical (Holdings) Limited - Company showcase

Year Founded & Workforce

1995

1,183 Employees

Dawnrays Pharmaceutical (Holdings) Limited logo

Dawnrays Pharmaceutical (Holdings) Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Dawnrays Pharmaceutical (Holdings) Limited Overview

Dawnrays is a vertically integrated, mid-sized Chinese generic pharmaceutical manufacturer controlled by a Hong Kong-incorporated holding structure and run from Suzhou. Its revenue is overwhelmingly domestic (99.7% in 1H2026) and dominated by finished drugs (93.1% of 1H2026 revenue), principally chronic-disease "system specific" medicines — the "An" amlodipine-based anti-hypertensive franchise, Fujian Dawnrays' statins and metformin, the Ruifuen entecavir anti-hepatitis-B tablet and the Xikewei/Xikexin antihistamines — supplemented by cephalosporin injectables and an upstream cephalosporin intermediates/API business that historically underpinned the Group's cost advantage. Since 2018, national volume-based procurement (VBP) has transformed the economics: volumes rose but prices fell, and two expensive plant relocations/new builds (Suzhou Shanfeng Road and Lanzhou) are still running well below capacity. The result is a highly cash-rich (≈RMB1.6bn cash and structured deposits), debt-free company trading below 0.4x book value, with a 25–50% payout policy and a stated pivot toward first-to-market generics, improved new drugs and external pipeline sourcing.


Company's own description

In its filings the Group describes itself as being principally engaged in developing, manufacturing and selling non-patented pharmaceutical medicines, spanning intermediate pharmaceuticals, bulk medicines (APIs) and finished drugs (1H26 IR, note 1.1). It reports two segments: (a) finished drugs, comprising antibiotic and non-antibiotic finished drugs; and (b) intermediates and bulk medicines (1H26 IR, note 2). Management characterises the Group's competitive basis as integration across R&D, production and sales, governance and sound financial management, anchored by a "Quality First, Integrity as Foundation" philosophy (FY24 AR-Ann, Outlook).

Independent characterisation

Dawnrays is best understood as three businesses with very different economics:

  1. Branded chronic-disease generics (the profit engine). "System specific medicines" accounted for 88.5% of finished-drug sales in 1H2026 (1H26 IR). The core franchises are anti-hypertensives (the "An" series built around amlodipine besylate tablets "Anneizhen"), lipid-lowering drugs (atorvastatin "Shumaitong", rosuvastatin, plus metformin SR "Yousuheng" from Fujian Dawnrays), antiviral entecavir dispersible tablets "Ruifuen", and antihistamines "Xikewei"/"Xikexin". These products carry high gross margins but are progressively exposed to national and alliance VBP rounds and to "price governance" campaigns that compress listing prices across channels.

  2. Cephalosporin injectables (cyclical, VBP-driven). Powder-for-injection products such as "Xianshu" (cefoperazone/sulbactam 1:1), "Xianlian" (2:1) and "Xianding" (cefotaxime) generated rapid growth in 2024–1H2025 after VBP wins, then fell 44.0% in 1H2026 as the continuation of VBP batches 1–8 reset prices (1H26 IR).

  3. Intermediates and APIs (loss-making, capacity in ramp-up). Historically the Group's origin (cephalosporin APIs such as cefoperazone sodium and ceftriaxone sodium; 2003 bulk sales were RMB210m, per the 2003 Annual Report), this segment now mainly supplies the Group's own formulation plants (intersegment sales RMB39.6m vs. external RMB37.6m in 1H2026). It lost RMB39.7m at the segment level in 1H2026 because the new Shanfeng Road plant in Suzhou and the Lanzhou base are under-utilised (1H26 IR).

Business and revenue model

DimensionCharacterisationEvidence
Revenue model~100% product sales, recognised at a point in time; immaterial pilot-test services (RMB2.0m in FY2024); no subscription or licensing revenueFY24 AR-Ann note 4; 1H26 IR note 3
Product vs. service mixProduct 99.8% / service 0.2% (FY2024); product 100% (1H2026)FY24 AR-Ann; 1H26 IR
Value-chain positionIntegrated from intermediates → API → finished dosage (cephalosporins); finished dosage only for most chronic-disease drugs (APIs partially in-house, e.g., new trelagliptin API at Lanzhou)1H26 IR; FY24 AR-Ann
Customer typesPharmaceutical distributors (main), hospitals via VBP tenders, pharmacy chains, primary-care/"third-terminal" outlets (village clinics, private institutions), e-commerce platforms; API customers (domestic formulators, overseas buyers)FY24 AR-Ann; 1H26 IR (Prospect)
Customer concentrationTop five customers ≈12% of sales; top five suppliers ≈27% of purchases (FY2025)FY25 AR summary
Credit termsGenerally three months for major customers; advance payment for new customers1H26 IR note 10
End-marketsCardiovascular (hypertension, hyperlipidaemia), metabolic (diabetes), infectious disease (HBV, bacterial infections), allergy, pain/inflammation, psychiatry (trazodone, newly approved), API exportFilings

Strategy

Stated strategic themes (paraphrased from FY2024 Chairman's Statement and 1H2026 Prospect)

FY2024 Outlook (four priorities, FY24 AR-Ann):

  1. Increase R&D investment — focus on chronic diseases, antivirals and anti-infectives; diversify into anti-ageing, nutrition and health; develop generics and innovative drugs with proprietary IP for domestic substitution.

  2. Enhance production efficiency — smart manufacturing, lean production and technological innovation to raise capacity utilisation.

  3. Expand market channels — deeper terminal coverage, e-commerce and international markets.

  4. Sustainable development — environmental infrastructure; carbon peak by 2030 and neutrality by 2060.

1H2026 Prospect (1H26 IR) refines this into:

  • Financial prudence, concentrating on products with clinical value, quality advantages and reasonable returns.

  • R&D: stronger project initiation assessment, milestone management and commercialisation hand-off; launch of trelagliptin and trazodone; external sourcing via universities, research institutes, innovative-drug companies and industry funds.

  • Quality/cost: GMP compliance, batch release, supply stability; production planned on actual orders to cut inefficient capacity and impairments.

  • Market: "terminal-actual-sales-oriented" approach prioritising market order, collection quality and channel inventory; omni-channel (hospitals, distributors, pharmacy chains, e-commerce); orderly international registration and customer sampling.

  • Digital/AI: unified data definitions, online processes, operational dashboards and intelligent analytics across finance, sales, production, quality, supply chain, R&D and HR.

  • Talent: precise recruitment for key positions, cadre evaluation, professional promotion tracks, performance and diversified incentives.

Initiatives announced in the last 24 months

DateInitiativeDetail / targetSource
2024–2025R&D organisational consolidationIntegration of all subsidiaries' R&D teams under the Suzhou institute; ~60% of pipeline self-developedFY24 AR-Ann
2,024Retail and e-commerce channel build-outDeeper pharmacy-chain partnerships; pharmaceutical e-commerce model launchedFY24 AR-Ann
Jun 2025Exit from Nanjing PharmaRaysSimplified R&D structureFY25 AR summary
Aug 2025Dawnrays Global Trading Ltd.New trading entity (international/trading purpose implied)FY25 AR summary
Mar 2026US$14m capital injection into Suzhou DawnraysStrengthen operating subsidiaryFY25 AR summary
Jun 2026Cadre management programmePhase I diagnosis and gap analysis complete1H26 IR
Jun–Jul 2026Biomedical venture fundUp to RMB100m commitment; access to deals, technology and returns1H26 IR
2,026Lanzhou phase IIRMB34.6m for new-product equipment and continuous-flow processes1H26 IR
2,026Shanfeng Road powder-mixing workshop~RMB17.8m1H26 IR
Jul 2026Share option grant10m options to employees1H26 IR

Medium-term targets and guidance

Management has not published quantitative revenue or margin targets. The only formal financial commitment is the dividend policy (payout of 25–50% of attributable profit, FY25 AR summary; earlier wording was "at least 25%", FY24 AR-Ann). Qualitative commitments: launch new products every year; achieve carbon peak by 2030 and neutrality by 2060.

Products & Services

Pricing models: all products are sold at tender/VBP-determined or negotiated listing prices to distributors and institutions; individual product prices are not disclosed.

Finished drugs — anti-hypertensives ("An" / 安 series)

Product / brandMolecule & descriptionTargetStatus / notesSource
Anneizhen (安內真)Amlodipine besylate tablets (5mg, 2.5mg passed consistency evaluation); flagship of "An" seriesHypertension patients; strong in second/third-tier terminalsApproved Feb 2004; VBP bid winner; management claims leading position among similar products in many cities/provinces' secondary and tertiary terminals2004 AR; FY24 AR-Ann
Losartan potassium and hydrochlorothiazide tablets (50/12.5mg)Fixed-dose ARB/diureticHypertensionPassed consistency evaluationFY24 AR-Ann
Telmisartan tablets (40mg, 80mg)ARBHypertensionPassed consistency evaluationFY24 AR-Ann
Telmisartan and amlodipine tablets (80mg/5mg)Fixed-dose combination, Class 4 chemical drugHypertensionApproved 1H20261H26 IR
Benidipine hydrochloride (process patents)Calcium channel blockerHypertensionInvention patents granted 2024; commercial status not disclosedFY24 AR-Ann

"An" series sales: RMB424.2m (FY2023), RMB334.3m (FY2024, 31.5% of group sales), RMB115.3m in 1H2026 (-28.1% YoY) (FY24 AR-Ann; 1H26 IR).

Finished drugs — lipid-lowering and metabolic (mainly Fujian Dawnrays)

Product / brandMolecule & descriptionTargetStatus / notesSource
Shumaitong (舒邁通)Atorvastatin calcium tabletsHyperlipidaemiaVBP bid winner; retail sales growthFY24 AR-Ann
Rosuvastatin calcium tabletsStatin; formulation and process patents granted 2024HyperlipidaemiaRecognised in Fujian's "New and Excellent" product list (Feb 2026)FY24 AR-Ann; 1H26 IR
Yousuheng (優素衡)Metformin hydrochloride sustained-release tablets (III)Type 2 diabetesWon alliance VBP renewal (2024); Fujian "New and Excellent" list (Feb 2026)FY24 AR-Ann; 1H26 IR
Metformin hydrochloride tablets (0.25g)BiguanideType 2 diabetesPassed consistency evaluationFY24 AR-Ann
Valsartan and amlodipine tabletsARB/CCB combination; patent granted 2024HypertensionFujian "New and Excellent" list (Feb 2026)FY24 AR-Ann; 1H26 IR
Trelagliptin succinate tablets (50mg, 100mg)Once-weekly DPP-4 inhibitor, Class 3 generic; API also approved (Lanzhou)Type 2 diabetesApproved 1H2026; launch preparation under way1H26 IR

Antihyperlipidaemic sales: RMB292.3m (FY2023), RMB299.4m (FY2024, 28.2%); Fujian Dawnrays solid-dose sales RMB178.6m in 1H2026 (+0.4%).

Finished drugs — antiviral

Product / brandDescriptionTargetStatusSource
Ruifuen (瑞夫恩)Entecavir dispersible tablets 0.5mg, using a proprietary cyclodextrin inclusion technologyChronic hepatitis BAlliance VBP winner; passed consistency evaluation; 2024 entecavir process invention patentFY24 AR-Ann

Sales: RMB124.8m (FY2023), RMB141.2m (FY2024, 13.3%), RMB97.6m in 1H2026 (+21.4%).

Finished drugs — anti-allergy

Product / brandDescriptionStatusSource
Xikewei (西可韋)Cetirizine hydrochloride tablets 10mgPassed consistency evaluationFY24 AR-Ann
Xikexin (西可新)Levocetirizine-class antihistamine (levocetirizine dihydrochloride tablets 5mg passed consistency evaluation; brand-molecule mapping per filings not explicitly confirmed)Passed consistency evaluationFY24 AR-Ann

Combined sales RMB38.0m in 1H2026 (+17.5%).

Finished drugs — antibiotics (cephalosporin powder for injection and oral)

Product / brandDescriptionStatusSource
Xianshu (先舒)Cefoperazone sodium and sulbactam sodium for injection (1:1), 1.0gWon 8th national VBP batchFY24 AR-Ann
Xianlian (先聯)Cefoperazone/sulbactam for injection (2:1), 1.5g and 3.0gAlliance VBP renewal winFY24 AR-Ann
Xianding (先定)Cefotaxime sodium for injection 1.0g/2.0gAlliance VBP winFY24 AR-Ann
Other injectables passing consistency evaluationCeftriaxone sodium, cefmetazole sodium (0.5g/1.0g), ceftazidime, cefuroxime sodium (0.75g/1.5g), cefminox sodium, cefoxitin sodium, cefazolin sodium, cefoperazone sodiumApprovedFY24 AR-Ann
Oral antibioticsAzithromycin tablets and suspension, clarithromycin tablets, cefprozil tablets, cefixime tablets (0.1g/0.2g)Passed consistency evaluationFY24 AR-Ann

Powder-for-injection sales: RMB76.2m (FY2023), RMB108.8m (FY2024, 10.3%), RMB51.7m in 1H2026 (-44.0%).

Other finished drugs

Product / brandDescriptionStatusSource
Zhen Tongyan (真侗言)Loxoprofen sodium tablets 60mg (NSAID)Alliance VBP win (2024)FY24 AR-Ann
Trazodone hydrochloride tablets (50mg, 100mg)Antidepressant, Fujian DawnraysApproved 1H20261H26 IR
Sitafloxacin aerosol, crisaboroleInvention patents granted 2024 (topical/anti-infective and dermatology); commercial status not disclosedPipeline/IPFY24 AR-Ann

Intermediates and bulk medicines

ProductSiteStatusSource
Cefoperazone sodium, sulbactam sodium and combination powder (sterile API)Suzhou Shanfeng RoadCommercial sales since 2024FY24 AR-Ann
Cephalosporin intermediatesLanzhouCommercial salesFY24 AR-Ann
Cephalosporin APIs, system-specific APIs, enzyme-inhibitor raw materials, health-supplement raw materialsLanzhou (planned product scope)Phase I in production; phase II (RMB34.6m) for new products and continuous-flow processesFY24 AR-Ann; 1H26 IR
Trelagliptin succinate APILanzhouApproved 1H20261H26 IR

I&B external sales: RMB129.4m (FY2023), RMB42.0m (FY2024), RMB37.6m in 1H2026; exports only RMB1.5m in 1H2026 (-85.7%).

Product revenue snapshot — half-year comparison

Product line1H20251H2026
"An" series anti-hypertensives (RMB M)160.3115.3
Fujian Dawnrays solid dose (RMB M)177.9178.6
Entecavir dispersible tablets (RMB M)80.497.6
Cephalosporin powder for injection (RMB M)92.251.7
Xikewei and Xikexin (RMB M)32.338.0
Intermediates and bulk medicines, external (RMB M)40.237.6

1H2026 values from 1H26 IR; 1H2025 values are analyst-derived by back-calculating from the disclosed 1H2026 growth rates (e.g., 97.624 / 1.214), except I&B which is reported.

Product revenue snapshot — full year

Product lineFY2023FY2024
"An" series (RMB M)424.2334.3
Antihyperlipidaemic products (RMB M)292.3299.4
Antiviral entecavir (RMB M)124.8141.2
Powder for injection (RMB M)76.2108.8
Intermediates and bulk medicines external (RMB M)129.442.0

Source: FY24 AR-Ann.

Financial Narrative

Income statement

Sources: FY2021–FY2024 EPS and profit from company results announcements (FY2021: 27 Mar 2022; FY2022: 26 Mar 2023; FY2023: 22 Mar 2024; FY2024: 28 Mar 2025); revenue, EBIT, EBITDA, pre-tax for FY2021–FY2022 and FY2025 from S&P/SA; FY2025 revenue, attributable profit and EPS from FY25 AR summary.

Adjusted ("operating") profit. Management's own normalised attributable profit, excluding the AD Pharmaceuticals disposal gain, the equipment subsidy and the associate's losses, was RMB250.0m (FY2023) and RMB201.7m (FY2024), down 19.3% (FY24 AR-Ann). FY2025 attributable profit of RMB214.0m contains a RMB33.9m intangible-asset impairment and RMB49.2m of inventory write-downs (FY25 AR summary), so underlying profitability was modestly higher than FY2024 on this basis.

Margins (%)

Revenue CAGR FY2021–FY2025: ~1.4% per year (analyst calculation, RMB1,165m → RMB1,230.9m). Over the same period EBIT fell at a ~12% CAGR, illustrating the margin compression from VBP and new-plant costs.

Interim trend: notes and sources

Source: 1H26 IR. 1H2026 profit grew 18.0% despite a 13.4% revenue decline, because selling expenses fell with a higher VBP mix (VBP products need less promotional spend), R&D dropped 38.4% after phased spending in 1H2025, and fair-value gains on financial assets rose to RMB21.1m from RMB4.5m. Inventory write-downs remained heavy at RMB26.5m.

Balance sheet

Sources: FY24 AR-Ann (FY2023–FY2024); 1H26 IR comparatives (FY2025 year-end); S&P/SA (FY2021–FY2022 and aggregated cash/investment line). Net cash per S&P includes trading securities and structured deposits.

30 June 2026 position (1H26 IR): total assets RMB3,987.9m; cash and bank balances RMB1,293.0m; FVTPL current financial assets RMB299.5m (mainly RMB287m principal-protected structured deposits from eight banks); borrowings only RMB4.5m (discounted notes); debt ratio 0.1%; net assets RMB3,432.2m (RMB2.278 per share); unused bank facilities ~RMB1.94bn.

Cash flow: notes and sources

Source: S&P/SA cash flow statement; FY2023–FY2024 OCF confirmed by FY24 AR-Ann (RMB338.4m and RMB220.2m). 1H2026 OCF RMB190.3m (1H2025: RMB202.0m); investing outflow RMB265.2m; financing outflow RMB133.6m (1H26 IR).

Ratios

ROE for FY2023, FY2024 and FY2025 matches company disclosures (11.4%, 17.0%, 6.3%). Other ratios are analyst calculations from the tables above. 1H2026: current ratio 5.38, quick ratio 4.88 (1H26 IR).

Working-capital cycle (company-disclosed days)

Payable days are not disclosed; trade payables are normally settled on 90-day terms (1H26 IR). An approximate cash conversion cycle using 90 payable days would be ~205 days (FY2024) and ~140 days (1H2026, analyst estimate).

Commentary on trends, inflections and drivers

FY2021–FY2022 (peak). Revenue reached ~RMB1.28bn in FY2022 as the 2019–2020 VBP wins (amlodipine, atorvastatin, entecavir and others) drove volume growth; EBIT margins sat near 33% and gross margins near 60%. The I&B segment was already slipping toward losses.

FY2023–FY2024 (VBP squeeze and relocation drag). Revenue fell 9.9% and 7.9% in successive years. The "An" series dropped from RMB424m to RMB334m in FY2024 as alliance procurement moved from single-winner to multi-winner formats and extended into retail, primary-care and private channels. Simultaneously, the Tianling Road plant relocation and Lanzhou start-up forced API customers to re-qualify the Group's products, collapsing external I&B sales by 67.5% in FY2024 and triggering RMB43.9m of inventory write-downs. Reported profit was nevertheless flattered by one-offs: RMB139.8m relocation compensation in FY2023 and RMB286.7m AD Pharmaceuticals gain plus a RMB105.0m pre-tax equipment subsidy in FY2024.

FY2025 (volume rebound, earnings normalisation). Revenue rebounded 16.1% to RMB1,230.9m, driven by cephalosporin injectables and resumed I&B sales, but attributable profit fell 62% to RMB214.0m because the FY2024 one-offs did not recur, R&D rose, and the Group booked RMB33.9m intangible impairment and RMB49.2m inventory write-downs (FY25 AR summary). Free cash flow of RMB269.4m was the strongest in five years as capex fell to RMB86.0m post-construction.

1H2026 (price reset, cost discipline). Revenue fell 13.4% as VBP batch 1–8 continuation pricing (effective 31 Mar 2026) hit powder injections (-44%) and price governance cut "An" series sales (-28%). Profit nevertheless rose 18% via lower selling, admin and R&D expenses plus higher fair-value gains. Quality of earnings is therefore lower than the headline suggests: management itself flags continuing impairment and gross-profit pressure on intermediates, APIs and injectables (1H26 IR).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityJurisdictionOwnershipRoleSource

Dawnrays Pharmaceutical (Holdings) Ltd.

Cayman Islands

Listed parent

Holding

1H26 IR

Dawnrays International Ltd. (formerly Dawnrays International Co. Ltd.)

BVI

100%

Intermediate holding; funds PRC subsidiaries (US$10m to Suzhou in 2024; US$14m in Mar 2026)

FY24 AR-Ann; FY25 AR summary

Dawnrays International Company Limited

Hong Kong

100%

Holding

Interim Report 2025 group chart

Dawnrays Pharma (Hong Kong) Ltd.

Hong Kong

100%

Holding/trading

Interim Report 2025 group chart

Dawnrays Biotechnology Capital (Asia) Ltd.

Hong Kong

100%

Investment vehicle (formerly held AD Pharmaceuticals stake)

FY24 AR-Ann

Dawnrays Global Trading Ltd.

—

100% (presumed)

Trading; established Aug 2025

FY25 AR summary

Top Field Limited

—100%

Holding company of Fujian Dawnrays; source of RMB241.2m goodwill

1H26 IR

Suzhou Dawnrays Pharmaceutical Co., Ltd.

PRC (Jiangsu)

100%

Main operating company; R&D institute; Shanfeng Road API/formulation plant

1H26 IR

Fujian Dawnrays Pharmaceutical Co., Ltd.

PRC (Putian, Fujian)

100%

Solid-dose chronic-disease generics (statins, metformin, valsartan/amlodipine, trazodone)

1H26 IR

Lanzhou Dawnrays Pharmaceutical Co., Ltd.

PRC (Gansu)

100%

Intermediates and API base (250 mu site)

FY24 AR-Ann

Suzhou Dawnrays Pharmaceutical Trading Co., Ltd.

PRC

100%

Pharma trading agency (not operational as of FY2024)

FY24 AR-Ann

Shanghai Jianxin Dawnrays Biomedical Industry Venture Capital Partnership (LP)

PRC

LP interest, up to RMB100m commitment (50%)

Venture fund; registered 28 Jul 2026

1H26 IR

Nanjing PharmaRays Science and Technology Co., Ltd.

PRC

Was 65%; disposed Jun 2025

Former R&D subsidiary

FY25 AR summary

“—” = not publicly disclosed.

Segment Overview

SegmentContentsProductsMeasurement basis

Finished drugs

Manufacture and sale of antibiotic and non-antibiotic finished drugs

"An" series, Fujian Dawnrays solid dose, entecavir, antihistamines, cephalosporin powder for injection, oral cephalosporins and other antibiotics

Segment result = adjusted profit before tax, excluding interest income, non-lease finance costs, government grants, dividend income, FV gains, head-office costs

Intermediates and bulk medicines

Manufacture and sale of intermediates and APIs (external + intersegment)

Cefoperazone sodium, sulbactam sodium and combination powder, other cephalosporin APIs and intermediates, specialty APIs (e.g., trelagliptin)

Same; intersegment sales at prevailing market prices

Revenue by Segment

MetricFY2021FY2022FY2023FY2024FY2025

Finished drugs revenue (CNY Mn)

1,0101,1401,021.71,018.31,160

Intermediates and bulk medicines total revenue incl. intersegment (CNY Mn)

216205210.1151.4177

Intersegment elimination (CNY Mn)

-61.4-64.6-80.6-109.3-107

Intermediates and bulk medicines external revenue (CNY Mn)

154.6140.4129.442.070

Group revenue (CNY Mn)

1,1651,2781,151.11,060.31,230.9

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Results by Segment and Segment Margins & Growth (%)

MetricFY2021FY2022FY2023FY2024FY2025

Finished drugs segment result (CNY Mn)

546609487.3425.2496

Intermediates and bulk medicines segment result (CNY Mn)

-2.3-17.8-32.7-61.0-69.5

Finished drugs segment margin (%)

54.153.447.741.842.8

Finished drugs share of group revenue (%)

86.789.288.896.094.3

Revenue by Segment and Segment Margins & Growth (%)

Metric1H20251H2026

Finished drugs revenue (CNY Mn)

590.2508.2

I&B external revenue (CNY Mn)

40.237.6

I&B intersegment revenue (CNY Mn)

45.539.6

Finished drugs segment result (CNY Mn)

250.9241.2

I&B segment result (CNY Mn)

-25.2-39.7

Finished drugs segment margin (%)

42.547.5

Income Statement and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (CNY Mn)

1,1651,2781,151.11,060.31,230.9

Revenue growth (%)

13.89.7-9.9-7.916.1

Gross profit, S&P standardised (CNY Mn)

675.4766.7628.5532.1557.4

Operating income / EBIT, S&P (CNY Mn)

380.8419.1276.0202.1227.4

EBITDA, S&P (CNY Mn)

433.9480.1354.4302.8343.7

Pre-tax income (CNY Mn)

439.3438.4414.1636.9249.6

Income tax (CNY Mn)

85.282.691.474.238.5

Profit for the year (CNY Mn)

354.2355.9322.7562.8211.1

Profit attributable to owners (CNY Mn)

358.2358.1326.0564.9214.0

EPS basic (MYR Bn)

0.23920.23890.21740.37540.14

EPS diluted (MYR Bn)

0.23750.23830.21700.37520.14

R&D expense (CNY Mn)

67.079.590.870.883.5

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Gross margin, S&P basis (%)

58.060.054.650.245.3

Gross margin, company basis (%)

58.060.055.754.545.3

Operating (EBIT) margin (%)

32.732.824.019.118.5

EBITDA margin (%)

37.237.630.828.627.9

Net margin, attributable (%)

30.728.028.353.317.4

Effective tax rate (%)

19.418.822.111.615.4

Income Statement and Per-Share Data

Metric1H20251H2026

Revenue (CNY Mn)

630.4545.8

Gross profit, company (CNY Mn)

314.0282.8

Selling and distribution expenses (CNY Mn)

56.839.4

Administrative expenses (CNY Mn)

67.562.1

R&D costs (CNY Mn)

56.835.0

Other expenses (CNY Mn)

33.130.5

Other income and gains (CNY Mn)

30.943.0

Profit before tax (CNY Mn)

130.3158.2

Profit attributable (CNY Mn)

104.6123.3

EPS basic (MYR Bn)

0.069610.08200

Balance Sheet

MetricFY2021FY2022FY2023FY2024FY2025

Total assets (CNY Mn)

3,3403,6733,622.74,009.34,009.4

Cash and bank balances (CNY Mn)

577.7811.7905.81,158.31,166.4

Cash plus short-term and trading investments, S&P (CNY Mn)

830.21,0821,1741,6081,805

Short-term borrowings (CNY Mn)

21.06.4120.129.977.5

Long-term debt incl. leases (CNY Mn)

2.52.00.54.90

Total debt (CNY Mn)

23.58.4120.534.777.5

Net cash (CNY Mn)

806.71,0731,0531,5731,727

Total equity (CNY Mn)

2,3982,6502,859.23,326.73,385.0

Goodwill (CNY Mn)

241.2241.2241.2241.2241.2

Inventories (CNY Mn)

203.5241.8211.1308.2215.4

Working capital (CNY Mn)

813.9811.91,051.31,647.61,799.7

Cash Flow

MetricFY2021FY2022FY2023FY2024FY2025

Operating cash flow (CNY Mn)

393.1434.3338.4220.2355.4

Capital expenditure (CNY Mn)

313.1204.4199.6126.086.0

Free cash flow (CNY Mn)

80.1229.9138.994.2269.4

Purchase of intangibles (CNY Mn)

90.021.312.549.633.4

Dividends paid (CNY Mn)

143.999.5117.1111.2132.9

Share buybacks (CNY Mn)

15.50000

Depreciation and amortisation (CNY Mn)

56.464.481.9104.5119.1

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2021FY2022FY2023FY2024FY2025

ROE, attributable profit / year-end attributable equity (%)

15.013.611.417.06.3

ROA, attributable profit / total assets (%)

10.79.79.014.15.3

ROIC, NOPAT / (equity + debt - cash and investments) (%)

19.321.611.910.211.6

Current ratio (x)

2.171.872.573.974.64

Debt to equity (%)

1.00.34.21.02.3

Net debt to EBITDA (x)

-1.86-2.24-2.97-5.19-5.02

Interest coverage, EBIT / interest expense (x)

5951,13327956455

Asset turnover, revenue / total assets (x)

0.350.350.320.260.31

Working Capital (Days)

MetricFY20241H2026

Trade receivable days

4844

Trade and notes receivable days

10185

Inventory days

194145

Revenue by Region and Revenue by Region (%)

RegionFY2023FY2024

Mainland China (CNY Mn)

1,134.41,049.0

Other countries (CNY Mn)

16.711.3

Mainland China share (%)

98.598.9

Revenue by Region and Revenue by Region (%) (1H2025–1H2026)

Region1H20251H2026

Mainland China (CNY Mn)

619.8544.3

Other countries (CNY Mn)

10.71.5

Mainland China share (%)

98.399.7

Revenue by Region

Segment and regionFY2023FY2024

Finished drugs — Mainland China (CNY Mn)

1,016.51,018.5

Finished drugs — other countries (CNY Mn)

5.30

I&B — Mainland China (CNY Mn)

118.030.5

I&B — other countries (CNY Mn)

11.511.3

Revenue by Region (1H2025–1H2026)

Segment and region1H20251H2026

Finished drugs — Mainland China (CNY Mn)

590.2508.2

I&B — Mainland China (CNY Mn)

29.636.1

I&B — other countries (CNY Mn)

10.71.5

Valuation Snapshot

MetricValueSource

Last price

HK$0.96 (8 Oct 2026)

S&P/SA

52-week change

-19.3% (as of 15 Sep 2026)

S&P/SA

50-day / 200-day moving average

HK$1.00 / HK$1.11 (15 Sep 2026)

S&P/SA

Year-to-date (to 31 Jul 2026)

~-15% (HK$1.04 close)

Zonebourse

Beta (5Y)

0.23

S&P/SA

Average daily volume (20 days)

~156,000 shares (very illiquid)

S&P/SA

Historical reference

Stock traded at ~HK$7.7 in Oct 2014 (pre-2018 2-for-1 split; ~HK$3.9 split-adjusted) per HKEX disclosure forms

HKEX DI

Valuation Multiples

MultipleDawnraysComment

P/E (TTM)

5.6x

S&P/SA

P/E (FY2025)

7.8x

MarketScreener

P/B

0.37x

S&P/SA

P/TBV

0.44x

S&P/SA

EV/Sales

Negative (~-0.06x on FY2025 basis)

MarketScreener; EV negative

EV/EBITDA

Negative / not meaningful

Net cash exceeds market cap

Dividend yield

~6.3% trailing

S&P/SA

Dividends & Capital Returns (HKD) and Returns & Leverage Ratios (%)

MetricFY2023FY2024FY2025

Interim dividend (HKD)

0.0150.0150.015

Final dividend (HKD)

0.0650.0480.048

Special dividend (HKD)

00.0320

Total dividend (HKD)

0.0800.0950.063

Payout ratio (%)

34.023.539.3

Analyst Conclusions

Management guidance

No numerical guidance. Management expects continued price compression for homogeneous generics, emphasises financial prudence, cost and supply competitiveness, launch of newly approved products (trelagliptin, trazodone), external pipeline sourcing, order-based production to reduce impairments, and orderly international registration (1H26 IR).

Consensus

None available.

Bull case

  1. Deep value with downside protection: at ~HK$1.45bn market cap the shares trade below net cash and liquid investments (~RMB1.6bn, ~HK$1.75bn) and at 0.37x book; even a modest earnings base supports a ~6% yield.

  2. Operating leverage from idle capacity: the I&B segment lost ~RMB70m in FY2025; converting Shanfeng Road and Lanzhou to break-even through API filings, trelagliptin API and exports would lift group pre-tax profit by roughly a quarter versus FY2025.

  3. Pipeline and channel replenishment: six approvals in 1H2026, 15 pending, and a funded M&A/venture channel could offset "An" series erosion, while entecavir (+21%) and antihistamines (+17.5%) are still growing.

Bear case

  1. Structural price deflation: VBP continuation and price governance drove a 13.4% revenue decline in 1H2026, and the 12th batch plus price-formation reforms imply further cuts.

  2. Value trap dynamics: controlled ownership, ~3% institutional ownership and thin liquidity mean the cash discount may never close; cash is being deployed into low-return plants and funds rather than buybacks.

  3. Earnings quality and impairment risk: recurring inventory write-downs (RMB26–49m per period), FV-gain-dependent profit growth, and RMB241m Fujian goodwill against flat Fujian sales.

Catalysts and monitorables (next 12 months)

  • 12th national VBP batch results and Dawnrays' winning products (expected late 2026).

  • Launch progress of trelagliptin and trazodone; CDE decisions on 15 pending applications.

  • I&B segment loss trajectory and Shanfeng Road utilisation in the FY2026 annual results (expected March 2027).

  • Collection of the remaining RMB175.6m relocation compensation.

  • HNTE tax-status renewal for Suzhou Dawnrays (from 2026).

  • Deployment of the RMB100m venture fund and any acquisition.

  • Any capital-return action (buyback or special dividend) given net cash.

  • Interim Report 2026 publication and FY2026 dividend decision.

Analyst verdict

Dawnrays is a financially conservative, cash-rich Chinese generic drug company whose core economics have been structurally reset by volume-based procurement. The finished-drug franchise still earns segment margins in the 40s and throws off strong cash (FY2025 free cash flow of RMB269m), and the balance sheet is exceptional for its size: roughly RMB1.6bn of cash and principal-protected deposits, negligible debt and RMB3.4bn of net assets. Against that, revenue has gone nowhere for five years (≈1.4% CAGR FY2021–FY2025), EBIT has fallen from RMB419m to RMB227m, and headline profits since 2023 have been propped up by one-offs (relocation compensation, the AD Pharmaceuticals sale, an equipment subsidy) and, in 1H2026, by fair-value gains and lower R&D spend.

The investment debate therefore centres on two questions. First, can management turn the ~RMB700m of upstream assets at Suzhou Shanfeng Road and Lanzhou from a ~RMB70m annual drag into a contributor? Evidence so far — falling external API sales, near-zero exports and repeated inventory write-downs — is not encouraging, although domestic API sales grew in 1H2026 and new APIs such as trelagliptin are now approved. Second, will the controlling shareholders allow the balance sheet to work harder for minority investors? The 25–50% payout policy and 6%+ yield are positives, but there have been no buybacks since 2021 even with the stock below net cash.

On balance, the shares look statistically cheap (≈5.6x trailing earnings, 0.37x book, negative enterprise value), and the downside is cushioned by cash. However, the absence of a visible growth engine, continuing VBP price resets in 2026, illiquidity and governance concentration argue that the discount is likely to persist without a catalyst. The stock is best viewed as a high-yield, low-beta value holding whose re-rating depends on demonstrable I&B break-even, successful new-product launches through the 12th VBP batch, or a decisive capital-return step.


Data gaps flagged (not publicly disclosed in materials reviewed): FY2025 product-level and geographic revenue; FY2025 company-basis gross profit; director and executive compensation; director ages and education; full institutional holder list; total patent portfolio; ESG emissions metrics and third-party ratings; 3- and 5-year share-price returns; subject of the 29 May 2026 Fujian Dawnrays announcement; Fujian Dawnrays acquisition date and price.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleCommitteesTenure / notesSource

Ms. LI Kei Ling (李其玲)

Executive Director, Chairman

Chair of Nomination; member of Remuneration

—

1H26 IR; AR2024 corporate information

Mr. HUNG Yung Lai (熊融禮)

Executive Director

——

1H26 IR

Mr. LEUNG Hong Man (梁康民)

Non-executive Director

—

Historical substantial holder (~6% in 2014 per HKEX disclosure of interests); absent from 22 May 2026 AGM

1H26 IR; HKEX DI forms

Mr. HU Shuo

Non-executive Director

—

Appointed 1 Aug 2025

MarketScreener (company announcement 31 Jul 2025)

Mr. LO Tung Sing Tony (勞同聲)

Independent Non-executive Director

Chair of Audit; member of Remuneration and Nomination

Absent from 2024 AGM

1H26 IR; FY24 AR-Ann

Mr. EDE, Ronald Hao Xi

Independent Non-executive Director

Chair of Remuneration; member of Audit and Nomination

Absent from 2024 AGM

AR2024; FY24 AR-Ann

Ms. LAM Ming Yee Joan (林明儀)

Independent Non-executive Director

Member of Audit, Remuneration and Nomination

—

AR2024; 1H26 IR

Executive Leadership Team

NameTitleTenureSource

Ms. 于麗偉 (Yu Liwei, pinyin rendering)

Chief Executive Officer (總裁)

Appointed 13 Sep 2024; holds share options under the 2023 scheme (FY25 AR summary notes options are held mainly by the CEO and employees)

AR2024 corporate information

Mr. 吳偉賢 (Wu Weixian, pinyin rendering)

Former CEO

Resigned 11 Sep 2024

AR2024 corporate information

Ms. Pang Kit Ling

Company Secretary

—

Board notice 14 Mar 2025

Dean, Suzhou Dawnrays Advanced Technology Research Institute (name not disclosed)

Head of Group R&D

Hired late 2024

FY24 AR-Ann

Board & Management Changes

DateChangeContext

11/13 Sep 2024

CEO transition from 吳偉賢 to 于麗偉

Coincided with plant ramp-up difficulties and R&D reorganisation

Late 2024

New Ph.D. dean of R&D institute

To consolidate R&D teams across Fujian, Suzhou, Lanzhou and Nanjing

1 Aug 2025

Hu Shuo appointed NED

Board expanded from 6 to 7

Jun 2026

Cadre management programme launched (phase I diagnostic complete)

Management-capability upgrade

3 Jul 2026

10,000,000 share options granted under 2023 scheme

Employee incentive

Major Shareholders

HolderApprox. stakeNotes / source

Fortune United Group Limited (BVI)

~39%

Ultimate holding company per 1H26 IR; stake per Simply Wall St (date of data not specified)

Ms. Li Kei Ling

~7.0%

Simply Wall St (date not specified)

Toyo International Investment Limited

~6.6%

Simply Wall St (date not specified)

Insiders (aggregate)

12.69%

S&P/SA, Sep 2026

Institutions (aggregate)

3.19%

S&P/SA, Sep 2026

Free float

~490m shares (~33%)

S&P/SA; public float ≥25% confirmed in FY25 AR summary

Competitive Landscape

Competitors by Segment

Segment / product areaCompetitorsRelative positioning

Amlodipine and other anti-hypertensives

Viatris (Pfizer legacy Norvasc), Zhejiang Huahai Pharmaceutical (sartans), CSPC Pharmaceutical Group, multiple VBP winners

Dawnrays strong in second/third-tier terminals (company claim), but faces multi-winner VBP dilution

Statins (atorvastatin, rosuvastatin)

Viatris (Lipitor), AstraZeneca (Crestor), Beijing Jialin (Lepu Medical), Qilu Pharmaceutical, Zhejiang Hisun

Fujian Dawnrays claims leading position in Chinese sales (company claim)

Entecavir

Bristol Myers Squibb (Baraclude), Chia Tai Tianqing (Sino Biopharmaceutical), Qilu, Jiangxi Qingfeng

Differentiated dispersible formulation; company claims a leading position

Cephalosporin injectables

Qilu Antibiotics, Reyoung Pharmaceutical, North China Pharmaceutical, Shandong Lukang, Hainan Poly Pharm, Joincare

Mid-sized participant; VBP-driven volatility

Cephalosporin intermediates/APIs

The United Laboratories (3933.HK, broader antibiotic API), Qilu Antibiotics, Shandong Lukang, ACS Dobfar (Italy), Indian API makers

Sub-scale; loss-making since capacity relocation

Antihistamines

UCB/Kenvue (Zyrtec), domestic generics (Suzhou and Jiangsu peers)

Niche

HK-listed generic peers (investor comparables)

SSY Group (2005.HK), The United Laboratories (3933.HK), China Medical System (0867.HK), Lee's Pharmaceutical (0950.HK)

Dawnrays is among the smallest by revenue

Peer Comparison FY2025

MetricDawnrays (2348.HK)The United Laboratories (3933.HK)SSY Group (2005.HK)

Revenue (local currency M)

RMB 1230.9

RMB 13210.6

HK$ 4165

Revenue growth YoY (%)

16.1-4.0-27.8

Gross margin (%)

45.341.741.6

Net margin, attributable (%)

17.415.811.3

R&D intensity (%)

6.87.05.9

Net cash / (debt) position

Net cash ~RMB1.7bn

Not computed

Net debt (borrowings HK$4,011m vs cash HK$1,691m)

Recent Developments

Headcount fell from 1,183 (end-2024) to 1,074 (Jun 2026), partly due to the Nanjing PharmaRays disposal.

Company Snapshot

$171.2M

Revenue

1,183

Employees

1995

Founded

P.O. Box, Cayman Islands

Headquarters

SWOT Analysis

Strengths

  • Fortress balance sheet: cash and bank balances RMB1,293.0m plus RMB299.5m FVTPL assets vs. RMB4.5m borrowings at 30 Jun 2026; debt ratio 0.1% (1H26 IR).
  • High-margin core franchise: finished-drug segment margin 47.5% in 1H2026 (RMB241.2m on RMB508.2m) (1H26 IR).
  • Entecavir momentum: Ruifuen sales +13.2% in FY2024 and +21.4% in 1H2026 to RMB97.6m (FY24 AR-Ann; 1H26 IR).
  • Comprehensive consistency-evaluated portfolio: 31 of 35 researched varieties approved by 31 Dec 2024 (FY24 AR-Ann).
  • Strong cash generation: FY2025 FCF RMB269.4m (21.9% margin) (S&P/SA).
  • Shareholder returns: dividends paid every year FY2021–FY2025 (RMB99.5m–RMB143.9m annually) with a 25–50% policy (S&P/SA; FY25 AR summary).

Weaknesses

  • Loss-making upstream segment: I&B segment loss RMB61.0m (FY2024), ~RMB69.5m (FY2025), RMB39.7m (1H2026) (FY24 AR-Ann; Zonebourse; 1H26 IR).
  • Earnings quality: FY2024 profit included RMB366.9m non-recurring gains; 1H2026 profit growth relied partly on RMB21.1m FV gains (FY24 AR-Ann; 1H26 IR).
  • Recurring impairments: inventory write-downs RMB43.9m (FY2024), RMB49.2m (FY2025), RMB26.5m (1H2026); intangible impairment RMB33.9m (FY2025).
  • Low capital efficiency: ROE fell to 6.3% in FY2025 from 15.0% in FY2021; asset turnover ~0.3x.
  • Scale disadvantage: FY2025 revenue RMB1.23bn vs. RMB13.2bn at United Laboratories.
  • Negligible exports: RMB1.5m in 1H2026 (0.3% of revenue) (1H26 IR).

Opportunities

  • New product launches: trelagliptin (tablets + in-house API) and trazodone approved in 1H2026, plus 15 applications pending (1H26 IR).
  • Capacity ramp-up leverage: Shanfeng Road and Lanzhou (combined planned investment >RMB1.05bn) could swing the I&B segment to profit if utilisation rises (FY24 AR-Ann).
  • Higher VBP entry thresholds (12th batch): stricter GMP, capacity and traceability requirements may reduce low-cost competitors (1H26 IR).
  • Retail and e-commerce channels: pharmacy-chain partnerships and e-commerce launched in 2024 (FY24 AR-Ann).
  • Pipeline M&A/in-licensing: RMB100m venture-fund commitment and large net cash enable external sourcing (1H26 IR).
  • Outstanding relocation compensation: RMB175.6m of RMB351.2m still to be collected (1H26 IR).

Threats

  • VBP continuation price resets: powder-for-injection sales -44% in 1H2026 (1H26 IR).
  • Price governance on brands: "An" series -28.1% in 1H2026 (1H26 IR).
  • Multi-winner dilution and channel expansion of alliance procurement to retail and private markets (FY24 AR-Ann).
  • Regulatory compliance cost escalation: unannounced inspections, data-integrity audits (FY24 AR-Ann).
  • Environmental/safety regulation for chemical API sites (FY25 AR summary risk section).
  • Goodwill risk: RMB241.2m Fujian goodwill depends on Fujian Dawnrays' value in use, whose solid-dose sales grew only 0.4% in 1H2026 (1H26 IR).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
23 Apr 2025Annual Report 2024 published HKEXConfirmed CEO change and board composition
23 May 2025AGM approves FY2024 final (HK$0.048) and special (HK$0.032) dividends MarketScreenerReturn of AD disposal proceeds
12 Jun 2025Final and special dividends paid FY24 AR-AnnCash outflow ~RMB112m
Jun 2025Disposal of 65% of Nanjing PharmaRays FY25 AR summaryR&D simplification
202511th national VBP batch introduces a four-dimensional evaluation mechanism FY25 AR summaryShifts competition beyond price
31 Jul 2025Appointment of Hu Shuo as NED (effective 1 Aug 2025) MarketScreenerBoard expansion
Aug 2025Dawnrays Global Trading Ltd. established FY25 AR summaryTrading/international capability
22 Aug 20251H2025 results: revenue +9.2% to RMB630m; attributable profit -78.8% to RMB105m Tiger Brokers; 1H26 IR comparativesNormalisation after FY2024 one-offs; strong powder-injection and API growth
11 Sep 2025Interim Report 2025 published HKEX—
3 Oct 2025Interim dividend HK$0.015 paid MarketScreener—
Jan 2026Fujian Dawnrays receives Licheng District special prize for economic contribution 1H26 IRLocal standing
Feb 2026Results of national VBP continuation for batches 1–8 announced (effective 31 Mar 2026) 1H26 IRTriggered price cuts on powder injections and some solid dose
Feb 2026Three Fujian products recognised in Fujian's second batch of "New and Excellent" medicines 1H26 IRBrand support
Mar 2026US$14m capital contribution to Suzhou Dawnrays FY25 AR summarySubsidiary funding
27 Mar 2026FY2025 results: revenue +16% to RMB1,230.9m; attributable profit -62% to RMB214.0m; final dividend HK$0.048 FY25 AR summary; MarketScreenerEarnings rebased; payout 39.3%
27 Mar 2026Utility model patent (weighing machine) granted 1H26 IRProcess IP
30 Mar 2026State Council General Office issues opinions on improving the drug price formation mechanism 1H26 IRFurther price transparency/listing-price governance
Apr 2026Two utility patents granted (14 and 24 Apr); Suzhou Dawnrays named a key biomedical enterprise in Wuzhong 1H26 IRIP; local recognition
~24 Apr 2026Annual Report 2025 published FY25 AR summaryDisclosed payout policy 25–50%, customer/supplier concentration
22 May 2026AGM approves FY2025 final dividend; NED Leung absent (CG code deviation) 1H26 IR; MarketScreenerGovernance
29 May 2026–
29 May 2026Utility patent (coating machine cleaning) granted 1H26 IRProcess IP
1H2026CDE approves telmisartan/amlodipine, trelagliptin tablets and API, and trazodone tablets 1H26 IRPipeline replenishment
12 Jun 2026FY2025 final dividend paid MarketScreener—
Jun 2026Cadre management programme launched 1H26 IROrganisational upgrade
18 Jun 2026LP agreement for biomedical venture fund (up to RMB100m) 1H26 IRNew strategic investment channel
23 Jun 202612th national VBP batch launched with stricter quality, GMP, IP, traceability and capacity requirements 1H26 IRRaises entry bar; favours compliant incumbents
3 Jul 202610m share options granted to employees 1H26 IRIncentives
28 Jul 2026Venture partnership registered 1H26 IRFund operational
28 Aug 20261H2026 results: revenue -13.4%; attributable profit +18.0%; interim dividend HK$0.015 1H26 IRCost-led earnings growth; top-line pressure
22–25 Sep 2026Ex-dividend (22 Sep) and record date (25 Sep) for interim dividend S&P/SA; 1H26 IR—
~9 Oct 2026Interim dividend dispatch date 1H26 IR—

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

10 charts
Income Statement: Revenue & Gross Profit (FY2021–FY2025): Revenue rose from CNY 1,165 Mn in FY2021 to CNY 1,230.9 Mn in FY2025.
Dawnrays Pharmaceutical (Holdings) Limited — Income Statement: Revenue & Gross Profit (FY2021–FY2025)
Series (CNY Mn)FY2021FY2022FY2023FY2024FY2025
Revenue1,1651,2781,151.11,060.31,230.9
Gross profit, S&P standardised675.4766.7628.5532.1557.4

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.